Celltrion Healthcare showcases positive 1-year data and budget impact analysis for novel subcutaneous formulation of infliximab in patients with rheumatoid arthritis at the European E-Congress of Rheumatology 2020
1-year data from a randomised controlled trial in patients with rheumatoid arthritis (RA) show no impact of body mass index...








